No association between whole-body ultraviolet A1 phototherapy and skin cancers in humans: a cancer registry linkage study

K. Bedair; A. Elhadad; S. Hamad; J. Ferguson; P. Donnan; R. S. Dawe

doi:10.1111/bjd.19041

No association between whole-body ultraviolet A1 phototherapy and skin cancers in humans: a cancer registry linkage study

K. Bedair, A. Elhadad, S. Hamad, J. Ferguson, P. Donnan, R. S. Dawe (Lead / Corresponding author)

Population Health and Genomics

Research output: Contribution to journal › Letter › peer-review

6 Citations (Scopus)

136 Downloads (Pure)

Abstract

Ultraviolet A1 (UVA1) phototherapy was first developed in the 1980s.1 Its use started in the UK in Dundee in 1996.2 It is not available in most centres despite being useful for some of the sclerosing/fibrosing conditions and granulomatous conditions. Where available, for some individuals, it can be very helpful for other indications such as atopic eczema.3 A concern is that sufficient exposures might increase the risk of skin cancer.4 Itt has been shown to produce cyclobutane-pyrimidine dimers in humans,5 and so has the potential to be carcinogenic.

Original language	English
Pages (from-to)	586-587
Number of pages	2
Journal	British Journal of Dermatology
Volume	183
Issue number	3
Early online date	20 Mar 2020
DOIs	https://doi.org/10.1111/bjd.19041
Publication status	Published - 1 Sept 2020

ASJC Scopus subject areas

Dermatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bjd.19041

Author Accepted ManuscriptAccepted author manuscript, 2.61 MB

Cite this

@article{81b0ad9af034432e8905d4aa50e70fdb,

title = "No association between whole-body ultraviolet A1 phototherapy and skin cancers in humans: a cancer registry linkage study",

abstract = "Ultraviolet A1 (UVA1) phototherapy was first developed in the 1980s.1 Its use started in the UK in Dundee in 1996.2 It is not available in most centres despite being useful for some of the sclerosing/fibrosing conditions and granulomatous conditions. Where available, for some individuals, it can be very helpful for other indications such as atopic eczema.3 A concern is that sufficient exposures might increase the risk of skin cancer.4 Itt has been shown to produce cyclobutane-pyrimidine dimers in humans,5 and so has the potential to be carcinogenic.",

author = "K. Bedair and A. Elhadad and S. Hamad and J. Ferguson and P. Donnan and Dawe, {R. S.}",

note = "Funding Information: The authors thank the Health Informatics Centre at the University of Dundee for providing access to databases and computational resources. Photosys, the database of Photonet, the National Managed Clinical Network for Phototherapy, was essential. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = sep,

day = "1",

doi = "10.1111/bjd.19041",

language = "English",

volume = "183",

pages = "586--587",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley",

number = "3",

}

TY - JOUR

T1 - No association between whole-body ultraviolet A1 phototherapy and skin cancers in humans

T2 - a cancer registry linkage study

AU - Bedair, K.

AU - Elhadad, A.

AU - Hamad, S.

AU - Ferguson, J.

AU - Donnan, P.

AU - Dawe, R. S.

N1 - Funding Information: The authors thank the Health Informatics Centre at the University of Dundee for providing access to databases and computational resources. Photosys, the database of Photonet, the National Managed Clinical Network for Phototherapy, was essential. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Ultraviolet A1 (UVA1) phototherapy was first developed in the 1980s.1 Its use started in the UK in Dundee in 1996.2 It is not available in most centres despite being useful for some of the sclerosing/fibrosing conditions and granulomatous conditions. Where available, for some individuals, it can be very helpful for other indications such as atopic eczema.3 A concern is that sufficient exposures might increase the risk of skin cancer.4 Itt has been shown to produce cyclobutane-pyrimidine dimers in humans,5 and so has the potential to be carcinogenic.

AB - Ultraviolet A1 (UVA1) phototherapy was first developed in the 1980s.1 Its use started in the UK in Dundee in 1996.2 It is not available in most centres despite being useful for some of the sclerosing/fibrosing conditions and granulomatous conditions. Where available, for some individuals, it can be very helpful for other indications such as atopic eczema.3 A concern is that sufficient exposures might increase the risk of skin cancer.4 Itt has been shown to produce cyclobutane-pyrimidine dimers in humans,5 and so has the potential to be carcinogenic.

UR - http://www.scopus.com/inward/record.url?scp=85083468647&partnerID=8YFLogxK

U2 - 10.1111/bjd.19041

DO - 10.1111/bjd.19041

M3 - Letter

C2 - 32198750

SN - 0007-0963

VL - 183

SP - 586

EP - 587

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 3

ER -

No association between whole-body ultraviolet A1 phototherapy and skin cancers in humans: a cancer registry linkage study

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Long-term and high exposure effects of the NB-UVB phototherapy in relation to increased risks of skin cancers: A 30- year retrospective cohort study (comparing with external standard) in Scotland - PHASE 1 (COHORT)

Cite this

No association between whole-body ultraviolet A1 phototherapy and skin cancers in humans: a cancer registry linkage study

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Projects

Long-term and high exposure effects of the NB-UVB phototherapy in relation to increased risks of skin cancers: A 30- year retrospective cohort study (comparing with external standard) in Scotland - PHASE 1 (COHORT)

Cite this